scholarly journals Hematopoietic Stem and Immune Cells in Chronic HIV Infection

2015 ◽  
Vol 2015 ◽  
pp. 1-7 ◽  
Author(s):  
Jielin Zhang ◽  
Clyde Crumpacker

Hematopoietic stem cell (HSC) belongs to multipotent adult somatic stem cells. A single HSC can reconstitute the entire blood system via self-renewal, differentiation into all lineages of blood cells, and replenishment of cells lost due to attrition or disease in a person’s lifetime. Although all blood and immune cells derive from HSC, immune cells, specifically immune memory cells, have the properties of HSC on self-renewal and differentiation into lineage effector cells responding to the invading pathogens. Moreover, the interplay between immune memory cell and viral pathogen determines the course of a viral infection. Here, we state our point of view on the role of blood stem and progenitor cell in chronic HIV infection, with a focus on memory CD4 T-cell in the context of HIV/AIDS eradication and cure.

JCI Insight ◽  
2021 ◽  
Author(s):  
Wouter A. van der Heijden ◽  
Lisa van de Wijer ◽  
Farid Keramati ◽  
Wim Trypsteen ◽  
Sofie Rutsaert ◽  
...  

2019 ◽  
Vol 14 (7) ◽  
pp. 579-582 ◽  
Author(s):  
Youdong Chen ◽  
Qian Yu ◽  
Yifan Hu ◽  
Yuling Shi

: Mesenchymal Stem Cells (MSCs) represent a heterogeneous group of self-renewal, multipotent non-hematopoietic stem cells, which display profound immunomodulatory functions and promising therapeutic effects. Autoimmune diseases, which result from an aberrant immune response to selfantigens, can be detrimental to nearly all body tissues. With the advance in developing a novel treatment, including biological agents, it is still impossible to cure autoimmune disorders. Recent studies demonstrate the remarkable therapeutic effectiveness of MSCs towards a wide array of autoimmune diseases. In this review, the immunomodulatory influence of MSCs over immune cells and the application of MSCs transplantation in treating autoimmune diseases are highlighted.


2020 ◽  
Vol 11 ◽  
Author(s):  
Maiko Sezaki ◽  
Yoshikazu Hayashi ◽  
Yuxin Wang ◽  
Alban Johansson ◽  
Terumasa Umemoto ◽  
...  

Lifelong blood production is maintained by bone marrow (BM)-residing hematopoietic stem cells (HSCs) that are defined by two special properties: multipotency and self-renewal. Since dysregulation of either may lead to a differentiation block or extensive proliferation causing dysplasia or neoplasia, the genomic integrity and cellular function of HSCs must be tightly controlled and preserved by cell-intrinsic programs and cell-extrinsic environmental factors of the BM. The BM had been long regarded an immune-privileged organ shielded from immune insults and inflammation, and was thereby assumed to provide HSCs and immune cells with a protective environment to ensure blood and immune homeostasis. Recently, accumulating evidence suggests that hemato-immune challenges such as autoimmunity, inflammation or infection elicit a broad spectrum of immunological reactions in the BM, and in turn, influence the function of HSCs and BM environmental cells. Moreover, in analogy with the emerging concept of “trained immunity”, certain infection-associated stimuli are able to train HSCs and progenitors to produce mature immune cells with enhanced responsiveness to subsequent challenges, and in some cases, form an inflammatory or infectious memory in HSCs themselves. In this review, we will introduce recent findings on HSC and hematopoietic regulation upon exposure to various hemato-immune stimuli and discuss how these challenges can elicit either beneficial or detrimental outcomes on HSCs and the hemato-immune system, as well as their relevance to aging and hematologic malignancies.


Blood ◽  
2019 ◽  
Vol 134 (Supplement_1) ◽  
pp. SCI-1-SCI-1
Author(s):  
Hitoshi Takizawa

Adult bone marrow (BM) had been long thought to be an immune-privileged organ where little immune reactions occur upon immunological challenges, and thus to form an advantageous environment to preserve long-lived hematopoietic and immune cells, e.g., hematopoietic stem cells (HSCs) that maintain lifelong hematopoiesis. They are mostly kept in quiescence, i.e., very slowly dividing within the steady state BM microenvironment, often referred to as niche, which consists of various type of non-hematopoietic cells such as endothelial cells, mesenchymal stromal cells1. In contrast, recent studies have suggested that a broad range of immunological and inflammatory responses occur in BM and largely influence HSC function2. Upon hematopoietic challenges, e.g., infection, inflammation, cancer, both HSCs and the surrounding niche cells can sense hematopoietic demand signals and integrate it to hematopoiesis via direct (HSC-mediated) and indirect (niche-mediated) sensing mechanisms. As a consequence, primitive HSC and their differentiated progenitors (HSPCs) migrate to inflamed organs, proliferate and differentiate into specific cell lineages that are locally consumed and to be replenished. Infection is one of hemato-immunological challenges that are highly conserved in evolution and relevant to pathogenesis of many diseases, e.g., cancer. Host defense against infection is initiated by rapid but relatively non-specific responses that involve innate immune effector cells, e.g., macrophages, granulocytes, and then is followed by slower but specific responses that involve acquired immunity. Recent studies have shown that not only immune cells but also HSPCs express innate immune sensors, such as Toll-like receptors (TLRs), and the ligation of receptors results in secretion of pro-inflammatory cytokines, cell migration, proliferation and differentiation into myeloid lineage cells (King, Nat Rev Immunol 2016). We have also shown that systemic infection of gram negative bacterial activates quiescent HSCs to proliferation through its cognate receptor, TLR4, and eventually impairs their hematopoietic repopulating ability3. More recently, we have found that intestinal tissue damage activates early hematopoiesis in BM via microbial signals and direct early HSPCs to inflamed lymph node to produce myeloid cells and promote tissue repair. Given the fact that innate immune cells are epigenetically programmed with innate immune memory upon sensitization ("training") infection to resist future infectious insults4, and that HSPCs are long-lived and immune-responsive, it has been demonstrated that upon exposure to pathogen, HSPCs also are able to memorize infection through metabolic and epigenetic changes, and build hemato-immune system with better protection to subsequent pathogen insults5. Taken together, these findings define the BM not as an immune-privileged reservoir, but rather as an organ of active immune reactions where immature HSPCs are capable of adapting the demand signal to hematopoiesis in response to hemato-immunological challenges, and of being trained by innate immune activation to reconstitute host defense with more resistance against future infection. Morrison SJ, Scadden DT. The bone marrow niche for haematopoietic stem cells. Nature. 2014 Jan 16;505(7483):327-34 Takizawa H, Boettcher S, Manz MG. Demand-adapted regulation of early hematopoiesis in infection and inflammation.Blood. 2012 Mar 29;119(13):2991-3002. Takizawa H, Fritsch K, Kovtonyuk LV, et al. Pathogen-Induced TLR4-TRIF Innate Immune Signaling in Hematopoietic Stem Cells Promotes Proliferation but Reduces Competitive Fitness.Cell Stem Cell. 2017 Aug 3;21(2):225-240.e5. Netea MG, Joosten LA, Latz E, et al. Trained immunity: A program of innate immune memory in health and disease.Science. 2016 Apr 22;352(6284):aaf1098. Kopf M, Nielsen PJ. Training myeloid precursors with fungi, bacteria and chips. Nat Immunol. 2018 Apr;19(4):320-322. Disclosures No relevant conflicts of interest to declare.


Blood ◽  
2008 ◽  
Vol 112 (11) ◽  
pp. 4358-4358
Author(s):  
Lung-Ji Chang ◽  
Yin Liang ◽  
Lily Lien ◽  
Chun- Rong Tong ◽  
Lu-Jia Dong ◽  
...  

Abstract Similar to virus infections, fungal infections are commonly seen in immunosuppressed transplant patients and can be life-threatening. Invasive Aspergillosis and Candidiasis are principal fungal infections among hematopoietic stem cell transplant (HSCT) patients, but Aspergillosis and other molds are the leading cause of deaths by fungal infections in immunocompromised allogeneic HSCT patients. The most effective treatment for fungal infections is preemptive and empirical anti-fungal therapies using agents such as fluconazole and amphotericin B deoxycholate (AmB-D). However, the success rate of antifungal therapy is generally low (in the 30–40% range) and associated with high toxicity. Both diagnosis and treatment for fungal infections are expensive and often ineffective. While improved formulations of AmB-D, second-generation triazoles, and echinocandins may be tolerable, newer generations of anti-fungal agents are very expensive. In animal studies, it has been shown that Aspergillosis can be successfully treated using Aspergillus-specific cytotoxic T cells (CTLs). Therefore, it is conceivable that CTLs specific to fungal antigens are effective in controlling fungal infections in allogeneic HSCT patients. To explore anti-fungal immune cell therapy, we used two different approaches to generate fungus-specific immune cells: Trichoderma and Rhizopus fungal lysates as antigen source to pulse dendritic cells (DCs), and pooled antigenic peptides to pulse DCs. The antigen-primed DCs were then co-cultured with lymphocytes to generate antigen-specific immune effector cells. The ex vivo generated anti-fungal immune cells displayed antigen-specific effector functions as illustrated by intracellular IFN-γ and CD107a staining. Interestingly, the fungus-specific immune effector cells are mostly CD4 T cells for all three species of fungal antigens. In a pilot clinical study, patients were selected when diagnosed with invasive aspergillosis based on galactomannan and beta-glucan assays, radiographs, CT scans, and/or blood cultures, or after an extended unsuccessful anti-fungal treatment with non-tolerable organ toxicity. Early indications suggest that the infusion of anti-fungal immune cells is safe, with therapeutic efficacy based on objective clinical evidence and importantly, is cost-effective. Nevertheless, more effective diagnosis and surveillance tools are needed to document the effectiveness of our anti-fungal immune cell treatment.


Cancers ◽  
2021 ◽  
Vol 13 (24) ◽  
pp. 6156
Author(s):  
Elena Anghileri ◽  
Monica Patanè ◽  
Natalia Di Ianni ◽  
Irene Sambruni ◽  
Martina Maffezzini ◽  
...  

The interpretation of the presence and function of immune infiltration in glioblastoma (GBM) is still debated. Over the years, GBM has been considered a cold tumor that is less infiltrated by effector cells and characterized by a high proportion of immunosuppressive innate immune cells, including GBM-associated microglia/macrophages (GAMs). In this context, the failure of checkpoint inhibitors, particularly in recurrent GBM (rGBM), caused us to look beyond the clinical results and consider the point of view of immune cells. The tumor microenvironment in rGBM can be particularly hostile, even when exposed to standard immunomodulatory therapies, and tumor-infiltrating lymphocytes (TILs), when present, are either dysfunctional or terminally exhausted. However, after checkpoint blockade therapy, it was possible to observe specific recruitment of adaptive immune cells and an efficient systemic immune response. In this review article, we attempt to address current knowledge regarding the tumor and immune microenvironment in rGBM. Furthermore, immunosuppression induced by GAMs and TIL dysfunction was revisited to account for genetic defects that can determine resistance to therapies and manipulate the immune microenvironment upon recurrence. Accordingly, we reevaluated the microenvironment of some of our rGBM patients treated with dendritic cell immunotherapy, with the goal of identifying predictive immune indicators of better treatment response.


Blood ◽  
2012 ◽  
Vol 120 (21) ◽  
pp. SCI-40-SCI-40
Author(s):  
Markus G. Manz

Abstract Abstract SCI-40 During systemic infection and inflammation, immune effector cells are in high demand and are rapidly consumed at sites of need. While adaptive immune cells have high proliferative potential, innate mature immune cells are mostly postmitotic and need to be replenished from bone marrow hematopoietic stem and progenitor cells. Indeed, severe clinical infection, particularly infections challenging the innate immune response, lead to an increase in hematopoietic differentiation and throughput in bone marrow, involving subsequent differentiation stages from hematopoietic stem cells, multipotent progenitors, as well as early-lineage and late-lineage restricted hematopoietic progenitors. A fundamental question is how the increased need is sensed and translated in enhanced production and how adequate levels of response are guided. Recent research has shed light on conserved intracellular and extracellular pathogen recognition receptors, such as Toll-like receptors, that are expressed on nonhematopoietic and hematopoietic effector cells and cause activation upon ligation. This activation results in production of hematopoietic growth, survival, activation, and migration factors operating at site on effector cells, but also at remote primary hematopoietic sites to increase production upon need. Recent research by several groups, including ours, surprisingly revealed that conserved pattern-recognition receptors are also expressed on hematopoietic stem and progenitor cells in bone marrow, implying a direct effect of systemically available ligands on these cellular populations. Indeed, it has been demonstrated that, for example, ligation of Toll-like receptor 4 by its cognate agonist lipopolysaccharide can lead to divisional activation, proliferation, lineage-directed differentiation, and migration of hematopoietic stem and lineage-restricted progenitor cells, all aimed at efficient contribution to immune responses and rapid reestablishment of hematopoietic homeostasis. The relative contribution of pathogen sensing by hematopoietic and diverse nonhematopoietic cells to appropriate hematopoietic responses, as well as the subcellular translation of the signals, is the focus of ongoing research. Also to be discussed will be how chronic infectious and inflammatory processes, which are frequently associated with aging, might impinge on hematopoiesis, potentially fostering hematopoietic stem cell diseases as exhaustion or transformation. Disclosures: No relevant conflicts of interest to declare.


Blood ◽  
2012 ◽  
Vol 119 (13) ◽  
pp. 2991-3002 ◽  
Author(s):  
Hitoshi Takizawa ◽  
Steffen Boettcher ◽  
Markus G. Manz

AbstractDuring systemic infection and inflammation, immune effector cells are in high demand and are rapidly consumed at sites of need. Although adaptive immune cells have high proliferative potential, innate immune cells are mostly postmitotic and need to be replenished from bone marrow (BM) hematopoietic stem and progenitor cells. We here review how early hematopoiesis has been shaped to deliver efficient responses to increased need. On the basis of most recent findings, we develop an integrated view of how cytokines, chemokines, as well as conserved pathogen structures, are sensed, leading to divisional activation, proliferation, differentiation, and migration of hematopoietic stem and progenitor cells, all aimed at efficient contribution to immune responses and rapid reestablishment of hematopoietic homeostasis. We also outline how chronic inflammatory processes might impinge on hematopoiesis, potentially fostering hematopoietic stem cell diseases, and, how clinical benefit is and could be achieved by learning from nature.


2013 ◽  
Vol 305 (10) ◽  
pp. E1185-E1194 ◽  
Author(s):  
Dimitrios Agas ◽  
Luigi Marchetti ◽  
Melania Capitani ◽  
Maria Giovanna Sabbieti

The microenvironment of bone marrow, an extraordinarily heterogeneous and dynamic system, is populated by bone and immune cells, and its functional dimension has been at the forefront of recent studies in the field of osteoimmunology. The interaction of both marrow niches supports self-renewal, differentiation, and homing of the hematopoietic stem cells and provides the essential regulatory molecules for osteoblast and osteoclast homeostasis. Impaired signaling within the niches results in a pathological tableau and enhances disease, including osteoporosis and arthritis, or the rejection of hematopoietic stem cell transplants. Discovering the anabolic players that control these mechanisms has become warranted. In this review, we focus on parathyroid hormone (PTH) and prostaglandins (PGs), potent molecular mediators, both of which carry out a multitude of functions, particularly in bone lining cells and T cells. These two regulators proved to be promising therapeutic agents when strictly clinical protocols on dose treatments were applied.


Sign in / Sign up

Export Citation Format

Share Document